Search

Your search keyword '"Kaushik, Ankita"' showing total 182 results
Start Over Author "Kaushik, Ankita"
182 results on '"Kaushik, Ankita"'

14. Stem Cells in the Mammalian Gonads

Author

Bhartiya, Deepa, Anand, Sandhya, Kaushik, Ankita, Sharma, Diksha, Crusio, Wim E., Series Editor, Lambris, John D., Series Editor, Rezaei, Nima, Series Editor, and Ratajczak, Mariusz Z., editor

Published
2019
Full Text
View/download PDF

30. Qualitative interviews to assess the impact of chronic hepatitis delta virus infection on health-related quality of life in untreated patients from the US, Italy, Spain, and Germany

Author

Lampertico, Pietro, primary, Gish, Robert G., additional, Reau, Nancy S., additional, Wedemeyer, Heiner, additional, Buti, Maria, additional, Elwick, Hannah, additional, Williamson, Nicola, additional, Chohan, Aishwarya, additional, Guy, Margaret, additional, Jones, Rowena, additional, Kaushik, Ankita, additional, and Yehoshua, Alon, additional

Published
2023
Full Text
View/download PDF

31. The impact of hepatitis D virus infection on health-related quality of life and fatigue in patients untreated for HDV: descriptive results from a cross-sectional study across Italy, Germany, Spain and the US

Author

Lampertico, Pietro, primary, Gish, Robert G., additional, Reau, Nancy S., additional, Wedemeyer, Heiner, additional, Buti, Maria, additional, Kaushik, Ankita, additional, Mirams, Laura, additional, Ellis, Hilary, additional, Taylor-Whiteley, Teresa, additional, and Yehoshua, Alon, additional

Published
2023
Full Text
View/download PDF

34. Real-World Value of Direct-Acting Antivirals for Hepatitis C at Kaiser Permanente Southern California.

Author

Nyberg, Lisa M., Kaushik, Ankita, Smith, Nathaniel, El Moustaid, Fadoua, Nyberg, Anders H., Su-Jau Yang, Chiang, Kevin M., and Yehoshua, Alon

Subjects
*DECISION trees, *COMPUTER simulation, *DISEASE progression, *HEPATITIS C, *ANTIVIRAL agents, *MEDICAL care, *MEDICAL care costs, *ACQUISITION of data, *TREATMENT effectiveness, *COMPARATIVE studies, *COST effectiveness, *DESCRIPTIVE statistics, *MEDICAL records, *RESEARCH funding, *STATISTICAL models, *LONGITUDINAL method
Abstract

OBJECTIVES: Direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) lead to cure in more than 95% of recipients; however, payers may limit access to these lifesaving drugs due to high initial cost. Here, the cost-effectiveness of treating HCV with DAAs vs no treatment over a lifetime horizon is evaluated from the perspective of Kaiser Permanente Southern California (KPSC). STUDY DESIGN: A hybrid decision-tree Markov model. METHODS: The model simulated the health and economic outcomes for a real cohort of patients with HCV treated with either ledipasvir-sofosbuvir or sofosbuvir-velpatasvir between November 1, 2014, and October 31, 2019, at KPSC. Patients entered the model at different stages of liver disease and received either active treatment with DAAs or no treatment. Patients who did not achieve sustained virological response experienced disease progression; those who achieved sustained virological response experienced either significantly slower or no disease progression depending on the stage of fibrosis at model start. Demographics, treatment experience, genotype, baseline fibrosis stage, treatment rates, and treatment efficacy were sourced from KPSC real-world data. Costs and utilities were sourced from published literature. RESULTS: A total of 7255 patients with a mean age of 59 years were treated during the study period. Over a lifetime horizon, DAAs resulted in significant reduction in advanced liver disease events and a total cost savings of $1 billion compared with no treatment based on a hybrid decision-tree Markov state-transition model. Cost savings were achieved after only 3 years. DAA intervention dominated no treatment on a per-patient and cohort basis. CONCLUSIONS: DAA treatment at KPSC is predicted to significantly reduce HCV-related morbidity and mortality, providing an anticipated return on investment in drug costs after 3 years of treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Treatment with Bulevirtide Improves Patient-reported Outcomes in Patients with Chronic Hepatitis Delta: An Exploratory Analysis of a Phase 3 Trial at 48 Weeks

Author

Buti, Maria, additional, Wedemeyer, Heiner, additional, Aleman, Soo, additional, Chulanov, Vladimir, additional, Morozov, Viacheslav, additional, Sagalova, Olga, additional, Stepanova, Tatyana, additional, Gish, Robert, additional, Lloyd, Andrew, additional, Kaushik, Ankita, additional, Suri, Vithika, additional, Manuilov, Dmitry, additional, Osinusi, Anu, additional, Flaherty, John, additional, and Lampertico, Pietro, additional

Published
2023
Full Text
View/download PDF

38. Characteristics associated with receipt of treatment among patients diagnosed with chronic hepatitis C virus.

Author

Gordon, Stuart C., Kaushik, Ankita, Chastek, Benjamin, Anderson, Amy, and Yehoshua, Alon

Subjects
*CHRONIC hepatitis C, *HEPATITIS C virus, *COMORBIDITY, *PEOPLE with mental illness, *SUBSTANCE-induced disorders, *OLDER patients
Abstract

Although current guidelines recommend that nearly all patients with chronic hepatitis C virus (HCV) infection receive treatment, a substantial proportion remain untreated. We conducted an administrative claims analysis to provide real‐world data on treatment patterns and characteristics of treated versus untreated patients among individuals with HCV in the United States. Adults with an HCV diagnosis from 01 July 2016 through 30 September 2020 and continuous health plan enrolment for 12 months before and ≥1 month after the diagnosis date were identified in the Optum Research Database. Descriptive and multivariable analyses were conducted to evaluate the association between patient characteristics and the rate of treatment. Of 24,374 patients identified with HCV, only 30% initiated treatment during follow‐up. Factors associated with increased rate of treatment included younger age versus age 75+ (hazard ratio [HR] 1.50–1.83 depending on age group), commercial versus Medicare insurance (HR 1.32), and diagnosis by a specialist versus a primary care physician (HR 2.56 and 2.62 for gastroenterology and infectious disease or hepatology, respectively) (p <.01 for all). Several baseline comorbidities were associated with decreased rate of treatment, including psychiatric disorders (HR 0.87), drug use disorders (HR 0.85) and cirrhosis (HR 0.42) (p <.01 for all). These findings highlight existing HCV treatment inequities, particularly among older patients and those with psychiatric disorders, substance use disorders or chronic comorbidities. Targeted efforts to increase treatment uptake in these populations could mitigate a considerable future burden of HCV‐related morbidity, mortality and healthcare costs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

Author

Buti, Maria, primary, Wedemeyer, Heiner, additional, Aleman, Soo, additional, Chulanov, Vladimir, additional, Viacheslav, Morozov, additional, Sagalova, Olga, additional, Stepanova, Tatyana, additional, Gish, Robert G., additional, Lloyd, Andrew, additional, Kaushik, Ankita, additional, Suri, Vithika, additional, Manuilov, Dmitry, additional, Osinusi, Anu, additional, Flaherty, John F., additional, and Lampertico, Pietro, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results